Thanks to a chance discovery, researchers have found a more efficient way to create induced pluripotent stem cells (iPSCs), which are widely
used in regenerative medicine research and drug development.
Not exact matches
Throughout 2017, ongoing clinical trials
in regenerative medicine using cord blood have offered hope to families facing life - changing medical conditions, such as cerebral palsy and autism.1 For some of these families, banking their baby's cord blood with ViaCord gave them the opportunity to participate
in this groundbreaking
research.
It can be
used in embryonic stem cell
research, or
in regenerative medicine where it is sometimes referred to as «therapeutic cloning.»
But a number of the invited speakers, including Alan Trounson, president of the California Institute for
Regenerative Medicine in San Francisco, and keynote speaker George Daley, a stem - cell scientist at Children's Hospital Boston
in Massachusetts, are involved
in research using human embryonic stem cells, which the Catholic Church considers unethical.
Applying a new method that is
used mainly
in stem - cell
research and
regenerative medicine, researchers from the Technical University of Munich have now devised a robust intestinal model for molecular
research into incretin release
in a test tube (
in vitro).
UCLA researchers led by Drs. Peiyee Lee and Richard Gatti at the Eli and Edythe Broad Center of
Regenerative Medicine and Stem Cell
Research have
used induced pluripotent stem cells (iPSC) to advance disease -
in - a-dish modeling of a rare genetic disorder, Ataxia Telangiectasia (A-T).
New
research by scientists at the Pennsylvania Cancer and Regenerative Medicine Research Center, a division of the Baruch S. Blumberg Institute, shows that medicines currently used in HIV treatment may help to target chemotherapy for breast
research by scientists at the Pennsylvania Cancer and
Regenerative Medicine Research Center, a division of the Baruch S. Blumberg Institute, shows that medicines currently used in HIV treatment may help to target chemotherapy for breast
Research Center, a division of the Baruch S. Blumberg Institute, shows that
medicines currently
used in HIV treatment may help to target chemotherapy for breast cancer.
Research by the Baruch S. Blumberg Institute's Pennsylvania Cancer and
Regenerative Medicine Research Center suggests that the
use of HIV drugs can allow for lower doses of chemotherapy
in treating breast cancer, reducing side effects
Lanza's
research focuses on the
use of stem cells and
regenerative medicine including nuclear transfer and stem cells
in human transplantation.
Dr. Masayo Yumoto, team leader of
Regenerative Medicine Research & Planning Division, Rohto Pharmaceutical Co., Ltd., has been holding a leadership role in the joint research lab at the Institute of Medical Sciences, University of Tokyo, to develop next generation cell culture method using human mesenchymal ste
Research & Planning Division, Rohto Pharmaceutical Co., Ltd., has been holding a leadership role
in the joint
research lab at the Institute of Medical Sciences, University of Tokyo, to develop next generation cell culture method using human mesenchymal ste
research lab at the Institute of Medical Sciences, University of Tokyo, to develop next generation cell culture method
using human mesenchymal stem cells.
RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX.V: RP), a clinical stage
regenerative medicine company focused on the development of autologous cell therapies, announced today the publication of a paper out of the University of Calgary
in conjunction with co-authors from Kyoto University and the University of North Carolina, which further validates the company's ongoing clinical
research using dermal sheath cup (DSC) cells to reverse the effects of pattern baldness.